Home > Dermatology > SPIN 2019 > Advances in Therapy > Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis

Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis

Expert
Prof. Peter van de Kerkhof, Radboud University Medical Center, the Netherlands
Conference
SPIN 2019

Prof. Peter van de Kerkhof (Radboud University Medical Center, the Netherlands) presented situations where dimethyl fumarate might be considered as a first-line treatment for psoriasis. Acitretin (synthesised retinoic acid) has a potent activity in pustular psoriasis and erythrodermic psoriasis as monotherapy. In chronic plaque psoriasis, it has a strong therapeutic activity, particularly in combination with phototherapy/UVB. Dimethyl fumarate and acitretin have a unique profile; in patients with contraindications for immunosuppressive therapies, both therapies may provide a solution [1].

Dimethyl fumarate has a very long history, particularly in German-speaking countries and the Netherlands. EMA registration has now been filed, after which regulated pharmacovigilance will be enforced and active research will be extended to enhance the proper use of this drug. The European Guidelines on the systemic treatment of psoriasis vulgaris recommends fumaric acid e...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on